Can I take mirabegron while pregnant or breastfeeding?
A plain-words look at what the NHS, the US drug label and LactMed say about mirabegron.
In short
Pregnancy: Mirabegron is not usually recommended in pregnancy.
Breastfeeding: You can take mirabegron while breastfeeding if your doctor or health visitor tells you your baby is healthy, although medicines that are better understood might be a better choice.
Your doctor, midwife or pharmacist can help you decide.
What this means for you
Pregnancy
- There isn't enough information to say whether or not it's safe to take while pregnant.
- If an overactive bladder has a big impact on your daily life, speak to your doctor, who may suggest other treatments.
Breastfeeding
- The amount of mirabegron that reaches breast milk is not known, but it's probably small.
When to get help
- Call 111 (NHS 111 in the UK) or get in touch with your health visitor, midwife, doctor or pharmacist as soon as you can if anything worries you, including if your baby is vomiting or has diarrhoea, is constipated, or shows signs of a urinary tract infection, such as irritability, a high temperature, and pee that smells different from normal.
Talk to your doctor or pharmacist
This page is educational, not advice for your own situation. Talk to your doctor, midwife or pharmacist before you start, stop or change any medicine in pregnancy or while breastfeeding.
The details: what each source says
Mirabegron in pregnancy
The NHS says
Mirabegron is not usually recommended in pregnancy. There isn't enough information to say whether or not it's safe to take while pregnant.
If an overactive bladder has a big impact on your daily life, speak to your doctor, who may suggest other treatments.
In our words, from the NHS page Mirabegron (nhs.uk). Contains public sector information licensed under the Open Government Licence v3.0 (OGL v3.0). The NHS does not endorse this site.
The US drug label says
8.1 Pregnancy Risk Summary There are no studies with the use of mirabegron in pregnant women or adolescents to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. Mirabegron administration to pregnant animals during organogenesis resulted in reversible skeletal variations (in rats) at 22-fold (via AUC) the maximum recommended human dose (MRHD) of 50 mg/day and decreased fetal body weights (in rabbits) at 14-fold the MRHD. At maternally-toxic exposures in rats (96-fold), decreased fetal weight and increased fetal mortality were observed and, in rabbits (36-fold), cardiac findings (fetal cardiomegaly and fetal dilated aortae) were observed [see Data]. The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risks of major birth defects or miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.
Prescribing label, section “8.1 Pregnancy” (opening excerpt): Mirabegron (oral), REMEDYREPACK INC. Read the full section on DailyMed. Quoted verbatim; US labels are written for US prescribers and patients.
Mirabegron while breastfeeding
The NHS says
You can take mirabegron while breastfeeding if your doctor or health visitor tells you your baby is healthy, although medicines that are better understood might be a better choice.
The amount of mirabegron that reaches breast milk is not known, but it's probably small.
Call 111 (NHS 111 in the UK) or get in touch with your health visitor, midwife, doctor or pharmacist as soon as you can if anything worries you, including if your baby is vomiting or has diarrhoea, is constipated, or shows signs of a urinary tract infection, such as irritability, a high temperature, and pee that smells different from normal.
In our words, from the NHS page Mirabegron (nhs.uk). Contains public sector information licensed under the Open Government Licence v3.0 (OGL v3.0). The NHS does not endorse this site.
LactMed says
No information is available on the use of mirabegron during breastfeeding. Because of moderately high protein binding and only relatively low bioavailability, exposure of the breastfed infant is likely to be low. If mirabegron is required by the mother, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
“Summary of Use during Lactation”, LactMed record “Mirabegron” (mirabegron), quoted verbatim. Everything LactMed reports about Mirabegron while breastfeeding.
The US prescribing label says
8.2 Lactation Risk Summary There are no data on the presence of mirabegron in human milk, the effects on the breastfed child, or the effects on milk production. Mirabegron-related material was present in rat milk and in the stomach of nursing pups following administrations of a single 10 mg/kg oral dose of 14 C-labeled mirabegron to lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mirabegron and any potential adverse effects on the breastfed child from mirabegron or from the underlying maternal condition.
Prescribing label, section “8.2 Lactation”: Mirabegron (oral), REMEDYREPACK INC. Label on DailyMed. Quoted verbatim; US labels are written for US prescribers and patients.
Other names
UK brand names (per the NHS): Betmiga.
Sources
- NHS, Mirabegron (nhs.uk), page last reviewed 21 July 2023. Paraphrased. Contains public sector information licensed under the Open Government Licence v3.0.
- US drug label: Mirabegron (oral), REMEDYREPACK INC., human prescription drug, label effective 3 September 2026, set ID 5f7a1758-8691-4e53-96d6-a01626ee8140. DailyMed (National Library of Medicine). Public domain; quoted verbatim.
- Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Mirabegron” (mirabegron), bulk release of 22 September 2026. LactMed on NCBI Bookshelf. Public domain; quoted verbatim. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Sources checked 26 September 2026. How we source and check every page.
Educational summary of named sources, not medical advice.